White-Berry Mistletoe (Viscum album L.) as complementary treatment in cancer: Does it help?

European Journal of Integrative Medicine

Volumn 3, Issue 2, 2011, Pages

  Bar Sela, Gil ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anthroposophic medicine; Cancer; Carcinoma; Mistletoe; Viscum album

Indexed keywords

FLAVONOID; GLYCOPROTEIN; KUTTAN PEPTIDE; LECTIN; OLIGOSACCHARIDE; PEPTIDE; POLYPEPTIDE; POLYSACCHARIDE; UNCLASSIFIED DRUG; VISCOTOXIN; VISCUM ALBUM EXTRACT;

ANAPHYLACTIC SHOCK; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; DIZZINESS; DRUG SYNTHESIS; EDEMA; ERYTHEMA; EXHAUSTION; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE; VISCUM ALBUM;

EID: 79961017270     PISSN: 18763820     EISSN: 18763839     Source Type: Journal    
DOI: 10.1016/j.eujim.2011.03.002     Document Type: Review

References (60)

1. Becker H. Botany of European mistletoe (Viscum album L.). Oncology 1986, 43(Suppl 1):2-7.
2. Dietrich J.B., Ribéreau-Gayon G., Jung M.L., Franz H., Beck J.P., Anton R. Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs 1992, 3:507-511.
3. Franz H. Mistletoe lectins their A and B chains. Oncology 1986, 43(Suppl 1):23-34.
4. Gabius H.J., Darro F., Remmelink M., André S., Kopitz J., Danguy A., et al. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 2001, 19:114-126.
5. Wiedłocha A., Sandvig K., Walzel H., Radzikowsky C., Olsnes S. Internalization and action of an immunotoxin containing mistletoe lectin A-chain. Cancer Res 1991, 51:916-920.
6. Zarkovic N., Vukovic T., Loncaric I., Miletic M., Zarkovic K., Borovic S., et al. An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 2001, 16:55-62.
7. Büssing A., Azhari T., Ostendorp H., Lehnert A., Schweizer K. Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer 1994, 30A:1836-1841.
8. Giudici M., Pascual R., de la Canal L., Pfüller K., Pfüller U., Villalaín J. Interaction of viscotoxins A3 and B with membrane model systems: implications to their mechanism of action. Biophys J 2003, 85:971-981.
9. Pal A., Debreczeni J.E., Sevvana M., Gruene T., Kahle B., Zeeck A., et al. Structures of viscotoxins A1 and B2 from European mistletoe solved using native data alone. Acta Crystallogr D Biol Crystallogr 2008, 64(Pt 9):985-992.
10. Schaller G., Urech K., Giannattasio M. Cytotoxicity of different viscotoxins and extracts from the European subspecies Viscum album L. Phytother Res 1996, 10:473-477.
11. Coulon A., Berkane E., Sautereau A.M., Urech K., Rouge P., Lopez A. Modes of membrane interaction of a natural cysteine-rich peptide: viscotoxin A3. Biochim Biophys Acta 2002, 1559:145-159.
12. Tabiasco J., Pont F., Fournié J.J., Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J Biochem 2002, 269:2591-2600.
13. Zee-Cheng R.K. Anticancer research on Loranthaceae plants. Drugs Future 1997, 22:519-530.
14. Kuttan G., Kuttan R. Reduction of leukopenia in mice by "viscum album" administration during radiation and chemotherapy. Tumori 1993, 79:74-76.
15. Mishra V., Bilgrami S., Sharma R.S., Kaur P., Yadav S., Krauspenhaar R., et al. Crystal structure of Himalayan mistletoe ribosome-inactivating protein reveals the presence of a natural inhibitor and a new functionally active sugar-binding site. J Biol Chem 2005, 280:20712-20721.
16. Müthing J., Meisen I., Bulau P., Langer M., Witthohn K., Lentzen H., et al. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. Biochemistry 2004, 43:2996-3007.
17. Kim Y.K., Kim Y.S., Choi S.U., Ryu S.Y. Isolation of flavonol rhamnosides from Loranthus tanakae and cytotoxic effect of them on human tumor cell lines. Arch Pharm Res 2004, 27:44-47.
18. Weis J., Bartsch H.H., Hennies F., et al. Complementary medicine in cancer patients: demand, patients' attitude and psychological beliefs. Onkologie 1998, 21:144-149.
19. Kaegi E. Unconventional therapies for cancer: 3 Iscador. Task force on alternative therapies of the Canadian breast cancer research initiative. CMAJ 1986, 158:1157-1159.
20. Stauder H.K. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 2002, 25:374-380.
21. Hutt N., Kopferschmitt-Kubler M., Cabalion J., Purohit A., Alt M., Pauli G. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol 2001, 29:201-203.
22. Hall A.H., Spoerke D.G., Rumack B.H. Assessing mistletoe toxicity. Ann Emerg Med 1986, 15:1320-1323.
23. Harmsma M., Grommé M., Ummelen M., Dignef W., Tusenius K.J., Ramaekers F.C. Differential effects of Viscum album extract Iscador Qu on cell cycle progression and apoptosis in cancer cells. Int J Oncol 2004, 25:1521-1529.
24. Kelter G., Schierholz J.M., Fischer I.U., Fiebig H.H. Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Anticancer Res 2007, 27:223-233.
25. Hunziker-Basler N., Zuzak T.J., Eggenschwiler J., Rist L., Simoes-Wust A.P., Viviani A. Prolonged cytotoxic effect of aqueous extracts from dried Viscum album on bladder cancer cells. Pharmazie 2007, 62:237-238.
26. Urech K., Buessing A., Thalmann G., Schaefermeyer H., Heusser P. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines. Anticancer Res 2006, 26:3049-3055.
27. Sagar S.M., Yance D., Wong R.K. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat. Curr Oncol 2006, 13:99-107.
28. Braun J.M., Blackwell C.C., Weir D.M., Beuth J. Cytokine release of whole blood from adult female donors challenged with mistletoe lectin-1 standardized mistletoe extract and E. coli endotoxin or phytohaemagglutinin. Anticancer Res 2003, 23:1349-1352.
29. Klopp R., Schmidt W., Niemer W., Werner M., Beuth J. Changes in immunological characteristics of white blood cells after administration of standardized mistletoe extract. In Vivo 2001, 15:447-457.
30. Stein G.M., Schaller G., Pfuller U., Wagner M., Wagner B., Schietzel M., et al. Characterisation of granulocyte stimulation by thionins, from European mistletoe and from wheat. Biochim Biophys Acta 1999, 1426:80-90.
31. Timoshenko A.V., Cherenkevich S.N., Gabius H.J. Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother 1995, 49:153-158.
32. Bussing A., Stumpf C., Troger W., Schietzel M. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res 2007, 27:2903-2910.
33. Lee S.J., Son Y.O., Kim H., Kim J.Y., Park S.W., Bae J.H., et al. Suppressive effect of a standardized mistletoe extract on the expression of activator NK receptors and function of human NK cells. J Clin Immunol 2007, 27:477-485.
34. Beuth J., Ko H.L., Schneider H., Tawadros S., Kasper H.U., Zimst H., et al. Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Res 2006, 26(6B):4451-4456.
35. Thies A., Dautel P., Meyer A., Pfuller U., Schumacher U. Low-dose mistletoe lectin-l reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer 2008, 98:106-112.
36. Mengs U., Schwarz T., Bulitta M., Weber K. Antitumoral effects of an intravesically applied aqueous mistletoe extraction urinary bladder carcinoma MB49 in mice. Anticancer Res 2000, 20:3565-3568.
37. Rostock M., Huber R., Greiner T., Fritz P., Scheer R., Schueler J., et al. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res 2005, 25:1969-1975.
38. Berger M., Schmähl D. Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors. J Cancer Res Clin Oncol 1983, 105:262-265.
39. Kuttan G., Kuttan R. Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett 1992, 66:123-130.
40. Renta R., Lyon E., Hunter R. Biologic properties of iscador: a Viscum album preparation I hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Lab Invest 1981, 44:43-48.
41. Gutsch J., Berger H., Scholz G., Denck H. Prospective study on radically operated breast cancer with polychemotherapy, helixor and untreated control. Deut Zeit Onkol 1988, 20:94-101.
42. Salzer G., Frey S., Danmayr E. Treatment of the operated stomach carcinoma at the Ludwig Boltzmann Institute for Clinical Oncology, Vienna. Deut Zeit Onkol 1990, 22:21-25.
43. Adjuvant cancer therapy in advanced non-small cell bronchial cancer: multicentric controlled studies to test the efficacy of iscador and polyerga 1991, Georg Thieme Verlag, Stuttgart, Germany. U. Dold, L. Edler, H. Mäurer (Eds.).
44. Kienle G.S., Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007, 12:103-109.
45. Horneber M.A., Bueschel G., Huber R., Linde K., Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008, 16:CD003297.
46. http://www.cancer.gov/cancertopics/pdq/cam/mistletoe/HealthProfessional/.
47. Gerhard I., Abel U., Loewe-Mesch A., Huppmann S., Kuehn J.J. Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer. Forsch Komplementarmed Klass Naturheilkd 2004, 11:150-157. [in German].
48. Elsässer-Beile U., Leiber C., Wolf P., Lucht M., Mengs U., Wetterauer U. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol 2005, 174:76-79.
49. Bar-Sela G., Goldberg H., Beck D., Amit A., Kuten A. Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Res 2006, 26:709-714.
50. Mebed M., El-Helw L., Sharma S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 2004, 90:65-69.
51. Bar-Sela G., Haim N. Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol 2004, 21:251-254.
52. Grossarth-Maticek R., Kiene H., Baumgartner S.M., Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001, 7:74-76. 57-66, 68-72.
53. Grossarth-Maticek R., Ziegler R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 2008, 13:107-120.
54. Kleeberg U.R., Suciu S., Bröcker E.B., Ruiter D.J., Chartier C., Liénard D., et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis. Eur J Cancer 2004, 40:390-402.
55. Augustin M., Bock P.R., Hanisch J., Karasmann M., Schneider B. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 2005, 55:38-49.
56. Bock P.R., Friedel W.E., Hanisch J., Karasmann M., Schneider B. Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 2004, 54:456-466.
57. Piao B.K., Wang Y.X., Xie G.R., Mansmann U., Matthes H., Beuth J., et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004, 24:303-310.
58. Steuer-Vogt M.K., Bonkowsky V., Ambrosch P., Scholz M., Neiss A., Strutz J., et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001, 37:23-31.
59. Goebell P.J., Otto T., Suhr J., Rubben H. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 2002, 168:72-75.
60. Lenartz D., Dott U., Menzel J., Schierholz J.M., Beuth J. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 2000, 20:2073-2076.